TG Therapeutics, Inc.
TGTX
$37.25
-$0.10-0.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 108.19M | 83.88M | 73.47M | 63.47M | 43.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 108.19M | 83.88M | 73.47M | 63.47M | 43.97M |
| Cost of Revenue | 15.40M | 9.34M | 8.30M | 5.44M | 7.85M |
| Gross Profit | 92.79M | 74.54M | 65.16M | 58.03M | 36.12M |
| SG&A Expenses | 38.96M | 41.97M | 38.79M | 34.58M | 31.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.24M | 71.45M | 64.65M | 72.74M | 56.46M |
| Operating Income | 29.95M | 12.43M | 8.82M | -9.27M | -12.49M |
| Income Before Tax | 25.45M | 4.27M | 6.55M | -10.68M | -14.03M |
| Income Tax Expenses | 2.12M | 388.00K | -328.00K | 29.00K | 390.00K |
| Earnings from Continuing Operations | 23.33M | 3.88M | 6.88M | -10.71M | -14.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.33M | 3.88M | 6.88M | -10.71M | -14.42M |
| EBIT | 29.95M | 12.43M | 8.82M | -9.27M | -12.49M |
| EBITDA | 29.96M | 12.45M | 8.84M | -9.24M | -12.45M |
| EPS Basic | 0.16 | 0.03 | 0.05 | -0.07 | -0.10 |
| Normalized Basic EPS | 0.11 | 0.02 | 0.03 | -0.05 | -0.06 |
| EPS Diluted | 0.15 | 0.02 | 0.04 | -0.07 | -0.10 |
| Normalized Diluted EPS | 0.10 | 0.02 | 0.03 | -0.05 | -0.06 |
| Average Basic Shares Outstanding | 145.24M | 145.10M | 144.73M | 146.21M | 143.09M |
| Average Diluted Shares Outstanding | 160.24M | 160.71M | 159.42M | 146.21M | 143.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
